FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099803755> ?p ?o ?g. }

• W2099803755 abstract "Background Stroke is a leading cause of death and disability world wide. Thrombolysis with recombinant tissue plasminogen activator (rt‐PA) is licensed for treatment of acute ischaemic stroke in the early hours after symptom onset. It has been shown in randomised controlled trials (RCTs) and the 2009 Cochrane review of thrombolysis for acute ischaemic stroke to reduce dependency but at the increased risk of intracranial haemorrhage. Methods to reduce the risk of haemorrhage while retaining or enhancing the benefit could increase the use of thrombolytic treatment. While most available information comes from RCTs of intravenous rt‐PA at 0.9 mg/kg, it is possible that other doses, drugs and other routes of administration might increase benefit and reduce the hazard. Objectives To assess the risks and benefits of different thrombolytic agents, doses and routes of administration for the treatment of acute ischaemic stroke. Search methods We searched the Cochrane Stroke Group Trials Register (May 2012), MEDLINE (1966 to May 2012) and EMBASE (1980 to May 2012). We handsearched journals and conference proceedings, searched ongoing trials registers and contacted pharmaceutical companies and researchers. Selection criteria Unconfounded randomised and quasi‐randomised trials of different doses of a thrombolytic agent, or different agents, or the same agent given by different routes, in people with confirmed acute ischaemic stroke. Data collection and analysis Two review authors independently assessed trial eligibility and quality, and extracted the data using a structured proforma. We cross‐checked and resolved discrepancies by discussion to reach consensus. We obtained translations and additional information from study authors where required. Main results We included 20 trials involving 2527 patients. Concealment of allocation was poorly described. Different doses (of tissue plasminogen activator, urokinase, desmoteplase or tenecteplase) were compared in 13 trials (N = 1433 patients). Different agents (tissue plasminogen activator versus urokinase, tissue‐cultured urokinase versus conventional urokinase, tenecteplase versus tissue plasminogen activator) were compared in five trials (N = 875 patients). Five trials (N = 485) compared different routes of administration. As some trials compared different agents and different doses, some patients contributed to two analyses. There was an approximately three‐fold increase in fatal intracranial haemorrhages in patients allocated to higher than to lower doses of the same thrombolytic drug (odds ratio (OR) 2.71, 95% confidence interval (CI) 1.22 to 6.04). There was no difference in the number of patients who were dead or dependent at the end of follow‐up between those allocated higher or lower doses of thrombolytic drug (OR 0.86, 95% CI 0.62 to 1.19). Higher versus lower doses of desmoteplase were associated with more deaths at the end of follow‐up (OR 3.21, 95% CI 1.23 to 8.39). There was no evidence of any benefit for intra‐arterial over intravenous treatment. Authors' conclusions These limited data suggest that higher doses of thrombolytic agents may lead to higher rates of bleeding. However, the evidence is inadequate to conclude whether lower doses of thrombolytic agents are more effective than higher doses, or whether one agent is better than another, or which route of administration is the best, for acute ischaemic stroke. At present, intravenous rt‐PA at 0.9mg/kg as licensed in many countries appears to represent best practice and other drugs, doses or routes of administration should only be used in randomised controlled trials." @default.
• W2099803755 created "2016-06-24" @default.
• W2099803755 creator A5012731608 @default.
• W2099803755 creator A5019056174 @default.
• W2099803755 creator A5028857433 @default.
• W2099803755 date "2013-05-31" @default.
• W2099803755 modified "2023-10-18" @default.
• W2099803755 title "Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke" @default.
• W2099803755 cites W132472807 @default.
• W2099803755 cites W1479785033 @default.
• W2099803755 cites W1900208830 @default.
• W2099803755 cites W1964540911 @default.
• W2099803755 cites W1969249790 @default.
• W2099803755 cites W1971247823 @default.
• W2099803755 cites W1972379989 @default.
• W2099803755 cites W1972869299 @default.
• W2099803755 cites W1979951595 @default.
• W2099803755 cites W1988328723 @default.
• W2099803755 cites W1997064745 @default.
• W2099803755 cites W2004287928 @default.
• W2099803755 cites W2006527876 @default.
• W2099803755 cites W2012982706 @default.
• W2099803755 cites W2016781450 @default.
• W2099803755 cites W2034433345 @default.
• W2099803755 cites W2042310162 @default.
• W2099803755 cites W2046166586 @default.
• W2099803755 cites W2046629096 @default.
• W2099803755 cites W2054441747 @default.
• W2099803755 cites W205495280 @default.
• W2099803755 cites W2056094715 @default.
• W2099803755 cites W2060969842 @default.
• W2099803755 cites W2090350362 @default.
• W2099803755 cites W2091694874 @default.
• W2099803755 cites W2105402180 @default.
• W2099803755 cites W2109663185 @default.
• W2099803755 cites W2111559905 @default.
• W2099803755 cites W2114603310 @default.
• W2099803755 cites W2122731734 @default.
• W2099803755 cites W2129357435 @default.
• W2099803755 cites W2133514192 @default.
• W2099803755 cites W2138812179 @default.
• W2099803755 cites W2143642806 @default.
• W2099803755 cites W2147542687 @default.
• W2099803755 cites W2148207944 @default.
• W2099803755 cites W2148738704 @default.
• W2099803755 cites W2153343266 @default.
• W2099803755 cites W2157281786 @default.
• W2099803755 cites W2165251895 @default.
• W2099803755 cites W2313603875 @default.
• W2099803755 cites W2399155639 @default.
• W2099803755 cites W2509084762 @default.
• W2099803755 cites W2521055826 @default.
• W2099803755 cites W2531503442 @default.
• W2099803755 cites W4210980547 @default.
• W2099803755 cites W4239471829 @default.
• W2099803755 cites W4254879268 @default.
• W2099803755 cites W70903732 @default.
• W2099803755 doi "https://doi.org/10.1002/14651858.cd000514.pub3" @default.
• W2099803755 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7045424" @default.
• W2099803755 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23728633" @default.
• W2099803755 hasPublicationYear "2013" @default.
• W2099803755 type Work @default.
• W2099803755 sameAs 2099803755 @default.
• W2099803755 citedByCount "43" @default.
• W2099803755 countsByYear W20998037552012 @default.
• W2099803755 countsByYear W20998037552014 @default.
• W2099803755 countsByYear W20998037552015 @default.
• W2099803755 countsByYear W20998037552016 @default.
• W2099803755 countsByYear W20998037552017 @default.
• W2099803755 countsByYear W20998037552019 @default.
• W2099803755 countsByYear W20998037552020 @default.
• W2099803755 countsByYear W20998037552021 @default.
• W2099803755 countsByYear W20998037552022 @default.
• W2099803755 countsByYear W20998037552023 @default.
• W2099803755 crossrefType "journal-article" @default.
• W2099803755 hasAuthorship W2099803755A5012731608 @default.
• W2099803755 hasAuthorship W2099803755A5019056174 @default.
• W2099803755 hasAuthorship W2099803755A5028857433 @default.
• W2099803755 hasBestOaLocation W20998037552 @default.
• W2099803755 hasConcept C126322002 @default.
• W2099803755 hasConcept C127413603 @default.
• W2099803755 hasConcept C168563851 @default.
• W2099803755 hasConcept C17744445 @default.
• W2099803755 hasConcept C177713679 @default.
• W2099803755 hasConcept C194828623 @default.
• W2099803755 hasConcept C199539241 @default.
• W2099803755 hasConcept C207103383 @default.
• W2099803755 hasConcept C2776572282 @default.
• W2099803755 hasConcept C2777377995 @default.
• W2099803755 hasConcept C2779473830 @default.
• W2099803755 hasConcept C2779581417 @default.
• W2099803755 hasConcept C2780645631 @default.
• W2099803755 hasConcept C2909817843 @default.
• W2099803755 hasConcept C3018755981 @default.
• W2099803755 hasConcept C3020166492 @default.
• W2099803755 hasConcept C44249647 @default.
• W2099803755 hasConcept C500558357 @default.
• W2099803755 hasConcept C535046627 @default.
• W2099803755 hasConcept C541997718 @default.
• W2099803755 hasConcept C71924100 @default.

• next